Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05648786 · ClinicalTrials.gov registry record · NA
Socializing a Science-Based Digital Therapeutic for Substance Use Disorders
A NA study of Substance Use Disorders and Substance-Related Disorders, sponsored by Square2 Systems.
- Active
- Registry status
- NA
- Development phase
- 189
- Enrollment target
- 1
- Study location
NCT05648786: Active NA study of Substance Use Disorders and Substance-Related Disorders, sponsored by Square2 Systems.
NCT05648786 is a NA study of Substance Use Disorders and Substance-Related Disorders that is active but no longer recruiting, run by Square2 Systems. The registered enrollment target is 189 participants, below the 498-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05648786, a NA study of Substance Use Disorders and Substance-Related Disorders, is active but no longer recruiting, sponsored by Square2 Systems.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 189 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness of an intervention delivered on a smartphone. This study examines whether this intervention might improve treatment outcomes for people with substance use disorders. The intervention, called Laddr®, is a smartphone application ("app") that provides information and skills that can help people stop using substances. The social version of Laddr® being tested in this study has new features that allow people in treatment for substance use disorders to include a support person in their treatment journey, including a friend, family member, or other acquaintance. This research study will compare the effectiveness of Laddr® in combination with standard outpatient substance use treatment to standard treatment only for substance use disorders.
Primary Outcome
Time between randomization and dropout from standard outpatient treatment
Conditions Studied
Interventions
- BEHAVIORAL Laddr® plus Behavioral- Group and individual counseling
- BEHAVIORAL Behavioral- Group and individual counseling
Study Locations (1)
New Hampshire
- Farnum Center - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
What the registry record for NCT05648786 still lists
NCT05648786 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, below the 498-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Laddr® plus Behavioral- Group and individual counseling is the first listed.
NCT05648786 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05648786 about?
NCT05648786 is a clinical study titled "Socializing a Science-Based Digital Therapeutic for Substance Use Disorders". The purpose of this study is to evaluate the effectiveness of an intervention delivered on a smartphone. This study examines whether this intervention might improve treatment outcomes for people with substance use disorders. The intervention, called Laddr®, is a smartphone application ("app") that p...
What is the current status of trial NCT05648786?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 189 participants. The study started on 2022-11-09. Estimated completion is 2024-12-31.
What conditions does trial NCT05648786 study?
This clinical trial studies the following conditions: Substance Use Disorders, Substance-Related Disorders.
What interventions are being tested in trial NCT05648786?
The interventions under investigation include: Laddr® plus Behavioral- Group and individual counseling (BEHAVIORAL), Behavioral- Group and individual counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT05648786?
This trial is sponsored by Square2 Systems, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05648786 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05648786's enrollment target sits among peer trials
189 36th of 93 higher than 58 of 93 other Substance Use Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
Families Left Behind
RECRUITING · NA
-
Trauma Screening/Referral and Interpersonal Violence Prevention for Women with Substance Use Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI